SEARCH

SEARCH BY CITATION

References

  • 1
    Valenstein M, Ganoczy D, McCarthy JF et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry 2006; 67: 154250.
  • 2
    Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 2007; 30: 43752.
  • 3
    Law MR, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 2008; 69: 4753.
  • 4
    Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55: 88691.
  • 5
    Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008; 8: 32. doi: DOI: 10.1186/1471-244X-8-32.
  • 6
    Möller HJ. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. Drugs 2007; 67: 154166.
  • 7
    Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 55364.
  • 8
    Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 120923.
  • 9
    Kahn RS, Fleischhacker WW, Boter H et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371: 108597.
  • 10
    Citrome L, Yeomans D. Do guidelines for severe mental illness promote physical health and well-being? J Psychopharmacol 2005; 6 (Suppl.): 1029.
  • 11
    Eli Lilly and Company. Zyprexa Olanzapine Tablets, Zyprexa Zydis Olanzapine Orally Disintegrating Tablets, Zyprexa IntraMuscular Olanzapine for Injection. http://pi.lilly.com/us/zyprexa-pi.pdf (accessed October 2007).
  • 12
    Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008; 69: 7909.
  • 13
    Mamo D, Kapur S, Keshavan M et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 2008; 33: 298304.
  • 14
    Nahata T, Saini TR. Optimization of formulation variables for the development of long acting microsphere based depot injection of olanzapine. J Microencapsul 2008; 25: 42633.
  • 15
    Eli Lilly and Company. Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder (HGKB). ClinicalTrials.gov Identifier: NCT00088465. http://clinicaltrials.gov/ct2/show/NCT00088465 (accessed July 2008).
  • 16
    Eli Lilly and Company. Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia (HGLQ). ClinicalTrials.gov Identifier: NCT00320489. http://clinicaltrials.gov/ct2/show/NCT00320489 (accessed July 2008).
  • 17
    Eli Lilly and Company. Comparison of intramuscular olanzapine depot with placebo in the treatment of patients with schizophrenia (HGJZ). ClinicalTrials.gov Identifier: NCT00088478. http://clinicaltrials.gov/ct2/show/NCT00088478 (accessed July 2008).
  • 18
    Eli Lilly and Company. Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and low-Dose Depot in Patients With Schizophrenia (HGKA). ClinicalTrials.gov Identifier: NCT00088491. http://clinicaltrials.gov/ct2/show/NCT00088491 (accessed July 2008).
  • 19
    Kurtz D, Bergstrom R, McDonnell DP, Mitchell M. Pharmacokinetics (PK) of multiple doses of olanzapine long acting injection (OLAI), an intramuscular (IM) depot formulation of olanzapine (OLZ), in stabilized patients with schizophrenia [abstract]. Biol Psychiatry 2008; 63: 288S.
  • 20
    Horne RL. Long Term Open Label Study of Olanzapine Pamoate: Efficacy and Effect on Weight [Abstract]. New Research Abstracts, 161st Annual Meeting of the American Psychiatric Association, 3–8 May 2008 Poster presentation NR5–117. Arlington, Virginia, USA: American Psychiatric Association, May 2008. http://www.psychiatry.org/Departments/EDU/Library/APAOfficialDocumentsandRelated/AbstractsAPAMeetings/2008NewResearchAbstracts.aspx (accessed August 2008).
  • 21
    Detke HC, McDonnell DP, Andersen SW, Watson SB. 160-week interim results from an open-label extension trial of olanzapine long-acting injection [abstract]. Int J Neuropsychopharmacol 2008; 11 (Suppl. 1): 151.
  • 22
    Detke HC, McDonnell DP, Kane JM, Naber D, Sethuraman G, Lin D. Olanzapine long-acting injection for the maintenance treatment of schizophrenia: a 24-week, randomized, double-blind trial [abstract]. Int J Neuropsychopharmacol 2008; 11 (Suppl. 1): 1512.
  • 23
    Detke HC, McDonnell DP, Lauriello J, Lambert T, Andersen SW, Lin D. Olanzapine long-acting injection: An 8-week double-blind. randomized, placebo-controlled study in acutely-ill patients with schizophrenia [abstract]. Int J Neuropsychopharmacol 2008; 11 (Suppl. 1): 152.
  • 24
    Gulliver A, McDonnell DP, Kryzhanovskaya LA, Zhao F, Detke HC, Feldman PD. Comparison of metabolic parameters during treatment for schizophrenia with olanzapine intramuscular long-acting injection versus olanzapine oral formulation [abstract]. Int J Neuropsychopharmacol 2008; 11 (Suppl. 1): 152.
  • 25
    Gulliver A, McDonnell DP, Sorsaburu S et al. Injection-related adverse events observed with olanzapine long-acting injection [abstract]. Int J Neuropsychopharmacol 2008; 11 (Suppl. 1): 152.
  • 26
    Gulliver A, Detke HC, McDonnell DP, Bergstrom RF, Lin D. Olanzapine long-acting injection: Pharmacokinetic and dose correspondence data relative to oral Olanzapine [abstract]. Int J Neuropsychopharmacol 2008; 11 (Suppl. 1): 1523.
  • 27
    Ascher-Svanum H, Montgomery W, Broabic A et al. Treatment completion rates of olanzapine and risperidone in long acting injectable formulations for the treatment of schizophrenia: a comparison of single arm open·label studies [abstract]. Int J Neuropsychopharmacol 2008; 11 (Suppl. 1): 1612.
  • 28
    Eli Lilly and Company. Zyprexa Olanzapine Pamoate (OP) Depot, Psychopharmacological Drugs Advisory Committee Briefing Document, 3 January 2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4338b1-03-Lilly.pdf (accessed August 2008).
  • 29
    Zhang J. Clinical Review NDA 22-173, Olanzapine Pamoate Depot, 4 January 2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4338b1-01-FDA.pdf (accessed August 2008).
  • 30
    Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand 2008; 117: 4129.
  • 31
    Citrome L, Kantrowitz J. Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Expert Rev Neurother 2008; 8: 107991.
  • 32
    Wagstaff AJ, Easton J, Scott LJ. Intramuscular olanzapine: a review of its use in the management of acute agitation. CNS Drugs 2005; 19: 14764.
  • 33
    Eli Lilly and Company. FDA Issues Not-Approvable Letter for Lilly’s Zyprexa Long-Acting Injection (LAI) for Schizophrenia Treatment, 28 February 2008. http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=296550 (accessed August 2008).
  • 34
    Kantrowitz J, Citrome L. Olanzapine: review of safety. Expert Opin Drug Saf 2008 (in press).